EcoDrugPlus

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSHBUG00000007379
Gene Symbol: HCAR1
2 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSHBUG00000003426
Gene Symbol: HCN4
3 Cross references
212 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSHBUG00000001942
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSHBUG00000006873
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter-Like

Ensembl ID : ENSHBUG00000001215
Gene Symbol: LOC102304737
3 Cross references
208 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSHBUG00000014982
Gene Symbol: LOC102314370
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSHBUG00000013461
Gene Symbol: IKBKB
3 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSHBUG00000004318
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSHBUG00000019305
Gene Symbol: LOC102293685
4 Cross references
257 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b-Like

Ensembl ID : ENSHBUG00000009711
Gene Symbol: LOC102312042
4 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSHBUG00000013397
Gene Symbol: INPP5D
3 Cross references
215 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSHBUG00000013474
Gene Symbol: LOC102292514
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).